CHENGDU HUASUN TECHNOLOGY GROUP INC. , LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.64 CNY | +1.11% |
|
+1.39% | -28.06% |
| Sales 2021 | 945M 130M | Sales 2022 | 873M 120M | Capitalization | 2.86B 395M |
|---|---|---|---|---|---|
| Net income 2021 | 70M 9.66M | Net income 2022 | 41M 5.66M | EV / Sales 2021 | 3.94 x |
| Net cash position 2021 | 257M 35.52M | Net Debt 2022 | 46.1M 6.36M | EV / Sales 2022 | 3.33 x |
| P/E ratio 2021 |
57.8
x | P/E ratio 2022 |
65
x | Employees | - |
| Yield 2021 |
0.16% | Yield 2022 |
0.22% | Free-Float | 73.04% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.11% | ||
| 1 week | +1.39% | ||
| Current month | -11.86% | ||
| 1 month | -11.44% | ||
| 3 months | -17.27% | ||
| 6 months | -30.67% | ||
| Current year | -28.06% |
1 week
3.44
3.66
1 month
3.354.45
Current year
3.025.33
1 year
3.025.87
3 years
3.027.86
5 years
3.027.86
10 years
3.0217.03
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Li
DFI | Director of Finance/CFO | 44 | - |
Ming Liang Huang
CHM | Chairman | 56 | - |
Duo Xue Wang
BRD | Director/Board Member | 40 | 20-03-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
You Su Zhou
BRD | Director/Board Member | 71 | 20-05-07 |
Xiao Ling Xin
BRD | Director/Board Member | 46 | 96-05-31 |
Yi Jian Huang
BRD | Director/Board Member | 45 | 17-04-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3.64 | +1.11% | 6,826,108 |
| 24-04-23 | 3.6 | +2.27% | 8,131,000 |
| 24-04-22 | 3.52 | -0.28% | 7,363,300 |
| 24-04-19 | 3.53 | -0.84% | 6,880,758 |
| 24-04-18 | 3.56 | -0.84% | 9,463,357 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Chengdu Huasun Technology Group Co Ltd, formerly Chengdu Taihe Health Technology Group Inc., Ltd., is principally engaged in manufacture and distribution of Chinese medicines and Western medicines, fabrication and installation services of steel structures, as well as production and sale of bio-engineering products. The Company primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The Company operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -28.06% | 315M | |
| +25.61% | 660B | |
| +22.95% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +13.04% | 219B | |
| -9.61% | 196B | |
| +6.49% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 000790 Stock
